

Board Composition Update

- **Dr Trevor Lockett and Mr Lou Panaccio retired from the RHY Board effective today.**
- **Ms Susan MacLeman steps down from the position of Deputy Chair to Non-Executive Director, effective 2 December 2024.**
- **Mr Gavin Fox-Smith to join the Board as Independent, Non-Executive Director, effective 2 December 2024.**

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (“**Rhythm**” or the “**Company**”) is pleased to provide an update on its Board Composition update, as previously announced on 30 September 2024 and 11 November 2024.

Retirements

Both Dr Trevor Lockett and Mr Lou Panaccio, who were directors prior to the Company’s ASX listing and having served in excess of 7 (seven) years on the Board have retired from the Board, prior to today’s Annual General Meeting.

Stepping Down

Ms Susan MacLeman will be stepping down from Deputy Chair to the position of Independent, Non-Executive Director as of 2 December 2024, following Mr Otto Buttula’s return to a Non-Executive role on 31 May 2024 and in the interests of achieving further cost savings.

New Independent, Non-Executive Director.

Mr Gavin Fox-Smith to join the Board, effective 2 December 2024.

The Board, at this time, believes the size, structure and composition of its current membership is proper, noting that Mr Otto Buttula intends to step down from the position of Chair when appropriate.

Rhythm Chairman, Otto Buttula, commented:

“On behalf of the whole Company, I would like to once again acknowledge Dr Lockett and Mr Panaccio for their service and contribution to the Company over the past 7 plus years. The Company wishes both Dr Lockett and Mr Panaccio well in their future endeavors. I would also like to thank Ms MacLeman for holding the position of Independent Deputy Chair at a challenging time.”

- ENDS -

Authorised for release by the Board.

For further information contact us via investors@rhythmbio.com:

Dr David Atkins Chief Executive Officer & Managing Director	Ms Andrea Steele Joint Company Secretary & General Counsel
--	--

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors
Otto Buttula Non-Executive Chairman
Sue MacLeman Non-Executive Director
David Atkins Managing Director & CEO

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.